<SEC-DOCUMENT>0001140361-21-021497.txt : 20210617
<SEC-HEADER>0001140361-21-021497.hdr.sgml : 20210617
<ACCEPTANCE-DATETIME>20210617190959
ACCESSION NUMBER:		0001140361-21-021497
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210615
FILED AS OF DATE:		20210617
DATE AS OF CHANGE:		20210617

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Ali-Jackson Kamil
		CENTRAL INDEX KEY:			0001654337

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		211026481

	MAIL ADDRESS:	
		STREET 1:		C/O ACLARIS THERAPEUTICS, INC.
		STREET 2:		101 LINDENWOOD DRIVE, SUITE 400
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-06-15</periodOfReport>

    <issuer>
        <issuerCik>0001472091</issuerCik>
        <issuerName>PDS Biotechnology Corp</issuerName>
        <issuerTradingSymbol>PDSB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001654337</rptOwnerCik>
            <rptOwnerName>Ali-Jackson Kamil</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PDS BIOTECHNOLOGY CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>25B VREELAND ROAD</rptOwnerStreet2>
            <rptOwnerCity>FLORHAM PARK</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07932</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-06-15</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>11764</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>8.5</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>11764</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>9.95</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2021-06-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-06-17</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>9000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald &amp; Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021.</footnote>
        <footnote id="F2">The Stock Option will vest in full and become fully exercisable on June 17, 2022.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Hillary Yegen, attorney-in-fact</signatureName>
        <signatureDate>2021-06-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
